Structure via PubChem · Public domain (PubChem)
hydromorphone
Sign in to saveAlso known as Dilaudid®, hydromorphone hydrochloride, Palladone®, Idromorfone, Dimorphone, Dihydromorphinone, Dihydromorfinon, 7,8-Dihydromorphinone
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464191262
- Drug.image
- Hydromorphone skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.alt
- Structural formula of hydromorphone
- Drug.width
- 180
- Drug.image2
- Hydromorphone molecule spacefill.png
- Drug.image_class2
- bg-transparent
- Drug.alt2
- Space-filling model of hydromorphone
- Drug.tradename
- Dilaudid, others
- Drug.MedlinePlus
- a682013
- Drug.DailyMedID
- Hydromorphone
- Drug.pregnancy_AU
- C
- Drug.dependency_liability
- High
- Drug.addiction_liability
- High
- Drug.routes_of_administration
- By mouth, intramuscular, intravenous, subcutaneous
- Drug.class
- Opioid
- Drug.ATC_prefix
- N02
via Wikipedia infobox
Chemical data
- Formula
- C17H19NO3
- Molecular weight
- 285.34 g/mol
- IUPAC name
- (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
- SMILES
- CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4
- InChIKey
- WVLOADHCBXTIJK-YNHQPCIGSA-N
- XLogP
- 1.8
- Polar surface area
- 49.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
2,879 papers- Hydromorphone.Journal of pain and symptom management · 2005
- Hydromorphone-OROS formulation.Expert opinion on pharmacotherapy · 2010
- Hydromorphone for cancer pain.The Cochrane database of systematic reviews · 2021
- Hydromorphone vs sufentanil in patient-controlled analgesia for postoperative pain management: A meta-analysis.Medicine · 2022
- Oral hydromorphone extended-release.The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2010
via PubMed
~17 min read
Encyclopedic overview
19 sectionsContents
- Side effects
- Hormone imbalance
- Neurotoxicity
- Withdrawal
- Interactions
- Pharmacology
- Formulations
- Pharmacokinetics
- Metabolism
- Chemistry
- Bacteria
- History
- Society and culture
- Names
- Legal status
- Use in executions
- Veterinary use
- References
- External links
Hydromorphone, also known as dihydromorphinone, and sold under the brand name Dilaudid among others, is a morphinan opioid used to treat moderate to severe pain. Typically, long-term use is only recommended for pain due to cancer. It may be used by mouth or by injection into a vein, muscle, or under the skin. Effects generally begin within half an hour and last for up to five hours. A 2016 Cochrane review (updated in 2021) found little difference in benefit between hydromorphone and other opioids for cancer pain.
Common side effects include dizziness, euphoria, sleepiness, nausea, itchiness, and constipation. Serious side effects may include abuse, low blood pressure, seizures, respiratory depression, and serotonin syndrome. Rapidly decreasing the dose may result in opioid withdrawal. Generally, use during pregnancy or breastfeeding is not recommended. Hydromorphone exerts its effects by activating opioid receptors, mainly in the brain and spinal cord. Hydromorphone 2 mg IV is equivalent to approximately 10 mg morphine IV.
Excerpted from Wikipedia’s “hydromorphone” article, available under the CC BY-SA 4.0 licence.